Vanguard Group Inc. Buys 75,348 Shares of Enovis Co. (NYSE:ENOV)

Vanguard Group Inc. grew its position in Enovis Co. (NYSE:ENOV - Free Report) by 1.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 5,486,130 shares of the company's stock after buying an additional 75,348 shares during the period. Vanguard Group Inc. owned approximately 9.65% of Enovis worth $240,731,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. UMB Bank n.a. lifted its position in Enovis by 128.2% in the 4th quarter. UMB Bank n.a. now owns 778 shares of the company's stock valued at $34,000 after acquiring an additional 437 shares in the last quarter. Pinnacle Bancorp Inc. raised its stake in shares of Enovis by 54.5% in the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock worth $37,000 after purchasing an additional 300 shares during the last quarter. FMR LLC lifted its holdings in shares of Enovis by 20.5% during the third quarter. FMR LLC now owns 2,840 shares of the company's stock valued at $122,000 after purchasing an additional 484 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Enovis during the third quarter valued at $217,000. Finally, Legacy Capital Wealth Partners LLC bought a new stake in Enovis in the 4th quarter worth about $228,000. Institutional investors own 98.45% of the company's stock.

Enovis Stock Performance

Shares of NYSE ENOV traded down $2.23 during midday trading on Thursday, hitting $32.00. 963,608 shares of the stock traded hands, compared to its average volume of 730,465. The firm has a market capitalization of $1.82 billion, a P/E ratio of -14.61 and a beta of 1.86. Enovis Co. has a one year low of $29.32 and a one year high of $60.61. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. The firm has a 50-day moving average of $39.13 and a two-hundred day moving average of $42.62.

Remove Ads

Enovis (NYSE:ENOV - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, beating analysts' consensus estimates of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company had revenue of $560.98 million for the quarter, compared to the consensus estimate of $555.14 million. On average, equities analysts forecast that Enovis Co. will post 2.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC restated a "buy" rating and set a $64.00 target price on shares of Enovis in a research note on Wednesday.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.